title: Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.
abstract: OBJECTIVE
  To evaluate the effect of golimumab on sleep disturbance in patients with active ankylosing spondylitis (AS).
  
  
  METHODS
  Golimumab was studied in a multicenter, randomized, placebo-controlled study (GO-RAISE). At baseline, 356 patients were randomly assigned in a 1.8:1.8:1 ratio to subcutaneous golimumab 50 mg, 100 mg, or placebo every 4 weeks. Sleep disturbance was assessed using the Jenkins Sleep Evaluation Questionnaire (JSEQ), which was administered at baseline, week 14, and week 24. Treatment effect was evaluated using analysis of variance on the van der Waerden normal scores.
  
  
  RESULTS
  Median JSEQ scores at baseline were 9.0 in the placebo group, 10.0 in the 50-mg group, and 11.0 in the 100-mg group, indicating moderate to severe sleep disturbance. Patients who received golimumab showed significantly greater median improvement from baseline in JSEQ scores compared with placebo at week 14 (-3.0 versus 0.0; P < 0.001) and week 24 (-3.0 versus -1.0; P < 0.001). Changes from baseline in JSEQ scores significantly correlated with changes from baseline in Short Form 36 summary scores, Bath AS Functional Index scores, total back pain, night back pain, and Bath AS Disease Activity Index scores. Multiple regression analyses indicated that improvement in the night back pain score was the most consistent predictor of change in JSEQ score or reduction in sleep disturbance.
  
  
  CONCLUSIONS
  Patients with active AS showed significant sleep disturbance at baseline due to underlying pain associated with AS. Treatment with subcutaneous golimumab every 4 weeks significantly reduced sleep disturbance and improved health-related quality of life.
authors.affiliation: Oregon Health & Science University, Portland, OR 97239, USA. deodhara@ohsu.edu
authors.forename: Atul
authors.initials: A
authors.lastname: Deodhar
authors.forename: Jürgen
authors.initials: J
authors.lastname: Braun
authors.forename: Robert D
authors.initials: RD
authors.lastname: Inman
authors.forename: Michael
authors.initials: M
authors.lastname: Mack
authors.forename: Shreekant
authors.initials: S
authors.lastname: Parasuraman
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Buchanan
authors.forename: Benjamin
authors.initials: B
authors.lastname: Hsu
authors.forename: Tim
authors.initials: T
authors.lastname: Gathany
authors.forename: Désirée
authors.initials: D
authors.lastname: van der Heijde
mesh_terms: D000704:Analysis of Variance; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005221:Fatigue / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008297:Male; D012893:Sleep Wake Disorders / Q000150:complications / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab